

ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2018-M3

Main

Labcode 603

Copyright © 2018
ECAT Foundation

Date of Issue : 13-November-2018

Survey : 2018-M3

Report : Main

Note:

In the Survey Manual 2018 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2018 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation on page 21 of the Survey Manual.

General InformationComplaints

Any complaints regarding this survey report should be reported to the ECAT before **January 4th, 2019**.

Complaints received after this date will not be taken into consideration.



P.Meijer
Executive Director

Note: A printed version of the actual Survey Manual is provided to all participants once a year. This manual can also be downloaded from the member section of the ECAT website.

ECAT Foundation

Director: Dr. P. Meijer
ECAT Office
P.O. Box 107
2250 AC Voorschoten, The Netherlands
phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919
E-mail: info@ecat.nl
Website: www.ecat.nl
VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102
General terms of delivery are applicable to all our services.

All rights reserved. No part of this report may be reproduced, stored in a retrieval system, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the ECAT Foundation.
Appendices are an integral part of the total report.

OVERVIEW Z-SCORES

Satisfactory ($-2 \leq Z\text{-score} \leq 2$)

Need attention ($-3 \leq Z\text{-score} < -2$ or $2 < Z\text{-score} \leq 3$)

Unsatisfactory ($Z\text{-score} < -3$ or > 3)

Module	Parameter	Sample	Total	Assay	Method
Coagulation Factor - I	Factor VIII (clotting activity)	18.113	-1.02	-1.06	-0.79
		18.114	0.34	0.32	1.10
	Factor IX	18.113	-0.12	-0.14	0.50
		18.114	0.26	0.26	-0.15
	Factor XI	18.113	-0.43	-0.44	-0.61
		18.114	-0.10	-0.12	-0.31
Factor XII	18.113	0.51	0.50	0.18	
	18.114	0.33	0.33	-0.16	
Coagulation Factor - II	Factor II	18.115	-1.36	-1.36	-0.86
		18.116	-1.42	-1.42	-1.25
	Factor V	18.115	-1.35	-1.35	-0.97
		18.116	-1.73	-1.73	-1.72
	Factor VII	18.115	-0.91	-0.91	-0.94
		18.116	-1.23	-1.23	-1.37
Factor X	18.115	-0.88	-0.88	-0.34	
	18.116	-0.73	-0.73	-0.12	
Von Willebrand Factor Parameters	VWF antigen	18.117	1.22	1.21	0.80
	VWF activity	18.117	1.99	0.57	0.44
	VWF Collagen Binding Assay	18.117	0.82	0.54	0.27
	VWF Factor VIII	18.117	0.29	0.26	
Factor XIII	Factor XIII activity (quantitative)	18.120	-0.44	-0.44	-0.56
		18.121	0.93	0.93	1.02
Fibrinolysis - I	Plasminogen activity	18.122	1.06	1.06	0.54
		18.123	0.48	0.48	0.89
	Plasmin Inhibitor	18.122	-0.13	-0.13	-0.29
Fibrinolysis - II	PAI-1 antigen	18.123	0.23	0.23	0.17
		18.124	-0.34	-0.34	
	t-PA antigen	18.125	0.80	0.80	
		18.124	-0.13	-0.13	
		18.125	-0.61	-0.61	

Coagulation Factor - I


Factor VIII (clotting activity)

Sample No 18.113
Sample Details Plasma with a low Factor XI level
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-April-2021
Homogeneity 0.0 % **Homogeneity Parameter** Factor XI
Number of Participants 345
Number of Responders 287 **Response Rate** 83 %
Comments One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.
 One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.


Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	249	13	6	10	9

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	285	71	0.48	9.1	55 - 116	64	-1.02
two-stage clotting assay	5	62			57 - 78		
Hyphen-Biomed Cephen	1	66					
IL HemosIL SynthASil	2	62			62 - 62		
Siemens Pathromtin SL	2	68			57 - 78		
one-stage clotting assay	280	71	0.48	9.0	55 - 116	64	-1.06
IL HemosIL APTT-SP liquid silica	14	68	3.14	13.8	55 - 84		
IL HemosIL SynthASil	89	69	0.75	8.2	57 - 100	64	-0.79
Other	2	87			69 - 105		
Sekisui Coagpia APTT-FS	1	69					
Siemens Actin	2	67			67 - 67		
Siemens Actin FS	36	71	1.13	7.6	60 - 94		
Siemens Actin FSL	22	74	1.81	9.2	63 - 90		
Siemens Pathromtin SL	31	72	1.33	8.2	64 - 82		
Stago Cephalin/Kaolin/CK Prest	37	72	0.91	6.2	58 - 81		
Stago Cephascreen	7	75			68 - 81		
Stago PTT (automate)/STA APTT	30	76	2.21	12.8	63 - 116		
Stago PTT-LA	1	63					
Tcoag Automated APTT	1	92					
Tcoag TriniClot APTT S	3	68			63 - 68		
Tcoag TriniClot APTT-HS	4	73			68 - 76		



Ringversuch ECAT 2018 / M3	Ergebnisse:	MW	Abgegeben	Zielwert	ZW(total)	Range	z-score	z-score total	Kommentar
Faktor VIII Probe 18.113 (50-150)	64,4	62,20	64	69	71	57 - 100	-0,79	-1,06	low factor XI
Faktor VIII Probe 18.114 (50-150)	35,2	41,46	41	38	40	25 - 47	1,1	0,32	moderate haemophilia B
Faktor IX Probe 18.113 (65-150)	106,5	104,70	107	102	108	75 - 126	0,5	-0,14	
Faktor IX Probe 18.114	7,5	7,70	8	8	7	5 - 12	-0,15	0,26	
Faktor XI Probe 18.113 (65-150)	20,2	19,65	20	22	22	16 - 36	-0,61	-0,44	
Faktor XII Probe 18.113 (50-150)	57,8	58,60	58	59	58	41 - 69	-0,31	-0,1	
Faktor XII Probe 18.114	129,4	104,68	100	99	96	82 - 111	0,18	0,51	
Faktor II Probe 18.115 (79-131)	60,8	60,25	61	61	59	48 - 73	-0,16	0,33	Normal coagulation plasma
Faktor II Probe 18.116 (79-131)	85,7	85,70	86	92	96	80 - 117	-0,86	-1,36	Plasma with a low Factor X
Faktor III Probe 18.115 (62-139)	18,9	18,90	19	21	23	18 - 25	-1,25	-1,42	
Faktor IV Probe 18.116 (62-139)	79,4	81,10	79	86	92	74 - 96	-0,97	-1,35	
Faktor V Probe 18.115 (50-129)	62,1	64,05	62	71	75	62 - 79	-1,72	-1,73	
Faktor VI Probe 18.116 (50-129)	100,9	103,65	101	105	108	96 - 129	-0,94	-0,91	
Faktor VII Probe 18.115 (50-150)	14,9	14,90	15	17	22	15 - 25	-1,37	-1,23	
Faktor VIII Probe 18.116 (50-150)	87,2	88,05	87	89	94	80 - 102	-0,34	-0,88	
Faktor XIII 18.120 (70-140) KC	9,7	9,75	10	10	11	8 - 12	-0,12	-0,73	
Faktor XIII 18.121	5,7	5,58	6	10	9	0 - 36	-0,56	-0,44	plasma factor XIII level <2%
von Willebrand 18.117	91,6	92,33	92	82	83	8 - 118	1,02	0,93	normal coagulation plasma
vWF Antigen (42-146 / 66-176)	40,3	40,90	42	39	35	21 - 44	0,8	1,21	plasma of type 2 von Willebrand disease
vWF:CBA (60-130)	22	24,50	27	24	23	15 - 66	0,54	0,82	most participants found a normal distribution in multimers
vWF:Aktivität (40/49 - 126/163)	29,6	29,70	30	27	21	17 - 51	0,44	1,99	
Faktor VIII (50-150)	7,4	7,20	7	7	7	3 - 20	0,26	0,26	
VWF:CB / VWF:Ag-Ratio	0,546	0,60							
VWF:AK / VWF:Ag-Ratio	0,734	0,73							
FVIII / VWF:Ag-Ratio	0,184	0,18							
Interpretation	VWD2N								
Fibrinolyse									
Plasminogen 18.122 (80.2 - 132)	50,8	49,95	51	49	44	25 - 59	0,54	1,06	VWD type 2
Plasminogen 18.123	91,3	90,65	91	88	89	77 - 94	0,89	0,48	Plasmin Inhibitor <5%
α2-Antiplasmin 18.122 (70-115)	8,6	9	9	10	9	2 - 23	-0,29	-0,13	Normal coagulation plasma
α2-Antiplasmin 18.123	103	101,50	103	102	101	75 - 131	0,17	0,23	
PAI-1 18.124 (4-43 ng/ml)	3,44	3,30	3,4	2,8	2,8	0,7 - 8,5	-0,34	-0,34	low PAI-1 level
PAI-1 18.125	88,56	88,6	88,6	84	60,6	4,7 - 119,8	0,8	0,8	elevated PAI-1
tPa 18.124 (2-8 ng/ml)	7,04	6,49	7	4,8	7,4	3,7 - 7	-0,13	-0,13	
tPa 18.125	2,76	2,49	2,8	2	4,1	1,7 - 3	-0,61	-0,61	
Lupus Antikoagulantien 18.112									
Lupussensitive PTT	53,7	1,75	1,77	1,77	1,54	1,46 - 2,26	-0,09	0,74	positive for LA (LA ratio approx. 1,6)
Spender	30,6								
1+1	42,9	1,4	1,63	1,39	1,39	1,05 - 1,85	-1,53	0,03	
dRVVT Screen (positiv>1,12)	48	1,53	1,42	1,4	1,4		0,98	1,02	
dRVVT Confirm	29,6								
Normalspender dRVVT Screen	31,38								
Normalspender dRVVT Confirm	26,6								
Ratio dRVVT Screen / Confirm	1,378								
SCT Screen (positiv > 1,26)	100,3	1,38	1,44	1,44	1,01		1,23	-0,42	
SCT Confirm	40,6	1,11	1,02	1,01	1,01		-0,14	-0,18	
Normalspender SCT Screen	39,2	2,56	2,6	2,6	2,62				
Normalspender SCT Confirm	35								
Ratio SCT Screen / Confirm	2,206	2,21	2,24	2,24				-0,08	
Interpretation	positiv								
HIT-I-Immunolegie									
18.128 U/ml	1,4	1,45	1,5	Mean 1,31 U/ml		0,9 - 1,9			
18.129 U/ml	0,8	0,85	0,9	Mean 0,79 U/ml		0,34 - 1,4			
Ringversuch ECAT 2018 / M2	Ergebnisse	MW	Abgegeben	Zielwert	ZW(total)	Range	z-score	z-score total	Kommentar



Coagulation Factor - I

Factor VIII (clotting activity)


Sample No 18.114
Sample Details Plasma of a patient with a moderate haemophilia B
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 25-June-2020
Homogeneity 5.8 % **Homogeneity Parameter** Factor IX
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 345
Number of Responders 287 **Response Rate** 83 %
Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 One participant did not report a result for this sample.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	4	6	25	243	8

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	282	40	0.33	11.2	21 - 71	41	0.34
two-stage clotting assay	5	33			33 - 43		
Hyphen-Biomed Cephen	1	36					
IL HemosIL SynthASil	2	33			33 - 33		
Siemens Pathromtin SL	2	38			33 - 43		
one-stage clotting assay	277	40	0.33	11.0	21 - 71	41	0.32
IL HemosIL APTT-SP liquid silica	13	36	1.18	9.6	21 - 46		
IL HemosIL SynthASil	88	38	0.44	8.7	25 - 47	41	1.10
Other	2	55			39 - 70		
Sekisui Coagpia APTT-FS	1	41					
Siemens Actin	2	39			37 - 40		
Siemens Actin FS	36	41	0.92	10.8	34 - 71		
Siemens Actin FSL	22	41	1.31	12.0	33 - 50		
Siemens Pathromtin SL	31	40	0.79	8.8	29 - 53		
Stago Cephalin/Kaolin/CK Prest	37	41	0.77	9.0	33 - 49		
Stago Cephascreen	7	45			41 - 50		
Stago PTT (automate)/STA APTT	29	43	1.17	11.8	33 - 67		
Stago PTT-LA	1	31					
Tcoag Automated APTT	1	51					
Tcoag TriniClot APTT S	3	39			39 - 41		
Tcoag TriniClot APTT-HS	4	38			38 - 42		




Coagulation Factor - I

Factor VIII (clotting activity)

Z-score plot



Z-score history



Coagulation Factor - I


Factor VIII (chromogenic)

Sample No 18.113
Sample Details Plasma with a low Factor XI level
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-April-2021
Homogeneity 0.0 % **Homogeneity Parameter** Factor XI
Number of Participants 345
Number of Responders 81 **Response Rate** 23 %
Comments None

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	62	7	4	4	4

Your Classification None

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	81	70	1.06	10.8	52 - 91		
Chromogenic assay	81	70	1.06	10.8	52 - 91		
Chromogenix Coamatic Factor VIII	22	66	1.82	10.3	52 - 75		
Chromogenix Coatest Factor VIII	5	63			60 - 83		
Hyphen Biomed. Biophen Factor VIII	28	74	1.62	9.2	53 - 90		
I.L. Electrachrome FVIII	1	70					
Other	11	70	2.87	10.9	62 - 91		
Siemens Factor VIII	11	70	2.36	8.9	55 - 79		
TCoag Trinchrom FVIII	1	68					
Technoclone Factor VIII	2	73			67 - 80		



Coagulation Factor - I


Factor VIII (chromogenic)

Sample No 18.114
Sample Details Plasma of a patient with a moderate haemophilia B
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 25-June-2020
Homogeneity 5.8 % **Homogeneity Parameter** Factor IX
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 345
Number of Responders 81 **Response Rate** 23 %
Comments One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	3	3	12	60	3

Your Classification None

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	80	43	0.78	13.2	25 - 54		
Chromogenic assay	80	43	0.78	13.2	25 - 54		
Chromogenix Coamatic Factor VIII	22	41	1.95	17.8	30 - 51		
Chromogenix Coatest Factor VIII	5	39			34 - 52		
Hyphen Biomed. Biophen Factor VIII	27	44	1.05	9.9	33 - 50		
I.L. Electrachrome FVIII	1	40					
Other	11	43	2.53	15.5	25 - 54		
Siemens Factor VIII	11	40	1.17	7.7	35 - 44		
TCoag Trinichrom FVIII	1	45					
Technoclone Factor VIII	2	47			41 - 53		







Coagulation Factor - I

Factor VIII (chromogenic)

Z-score plot



Z-score history



Coagulation Factor - I


Factor IX

Sample No 18.113
Sample Details Plasma with a low Factor XI level
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-April-2021
Homogeneity 0.0 % **Homogeneity Parameter** Factor XI
Number of Participants 345
Number of Responders 280 **Response Rate** 81 %
Comments One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	270	1	0	3	6

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	279	108	0.92	11.3	11 - 152	107	-0.12
one-stage clotting assay	273	108	0.92	11.2	11 - 152	107	-0.14
IL HemosIL APTT lyophilised silica	2	102			102 - 103		
IL HemosIL APTT-SP liquid silica	12	100	5.56	15.5	83 - 126		
IL HemosIL SynthAsil	89	102	1.14	8.4	75 - 126	107	0.50
Medica Tec APTT-P	1	104					
Sekisui Coagpia APTT-FS	1	106					
Siemens Actin	2	108			107 - 108		
Siemens Actin FS	34	111	2.12	8.9	94 - 139		
Siemens Actin FSL	20	114	3.05	9.6	99 - 141		
Siemens Pathromtin SL	33	106	1.87	8.1	84 - 133		
Stago Cephalin/Kaolin/CK Prest	37	112	1.82	7.9	96 - 135		
Stago Cephascreen	7	133			109 - 140		
Stago PTT (automate)/STA APTT	27	121	4.39	15.1	11 - 152		
Tcoag Automated APTT	1	121					
Tcoag TriniClot APTT S	3	120			89 - 126		
Tcoag TriniClot APTT-HS	4	104			24 - 112		
two-stage clotting assay	6	95			91 - 115		
Hyphen-Biomed Cephen	1	95					
IL HemosIL SynthAsil	2	91			91 - 91		
Other	2	112			108 - 115		
Siemens Pathromtin SL	1	94					



Coagulation Factor - I

Factor IX

Sample No 18.114
Sample Details Plasma of a patient with a moderate haemophilia B
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 25-June-2020
Homogeneity 5.8 %

Homogeneity Parameter Factor IX

For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 345

Number of Responders 280


Response Rate 81 %

Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 One participant did not report a result for this sample.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	1	0	0	272	6

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	272	7	0.16	30.8	2 - 101	8	0.26
one-stage clotting assay	266	7	0.17	31.0	2 - 101	8	0.26
IL HemosIL APTT lyophilised silica	2	8			7 - 8		
IL HemosIL APTT-SP liquid silica	11	7	0.53	21.4	5 - 11		
IL HemosIL SynthAsil	88	8	0.17	16.6	5 - 12	8	-0.15
Medica Tec APTT-P	1	8					
Sekisui Coagpia APTT-FS	1	7					
Siemens Actin	2	6			6 - 6		
Siemens Actin FS	33	8	0.34	20.2	5 - 15		
Siemens Actin FSL	20	6	0.38	21.6	4 - 10		
Siemens Pathromtin SL	31	9	0.91	46.4	4 - 18		
Stago Cephalin/Kaolin/CK Prest	36	5	0.23	23.5	2 - 7		
Stago Cephascreen	7	8			7 - 9		
Stago PTT (automate)/STA APTT	26	5	0.33	25.9	4 - 101		
Tcoag Automated APTT	1	8					
Tcoag TriniClot APTT S	3	7			3 - 9		
Tcoag TriniClot APTT-HS	4	9			6 - 9		
two-stage clotting assay	6	6			5 - 10		
Hyphen-Biomed Cephen	1	6					
IL HemosIL SynthAsil	2	6			6 - 6		
Other	2	8			5 - 10		
Siemens Pathromtin SL	1	7					




Coagulation Factor - I

Factor IX

Z-score plot



Z-score history




Coagulation Factor - I **Factor XI**

Sample No 18.113
Sample Details Plasma with a low Factor XI level
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-April-2021
Homogeneity 0.0 % **Homogeneity Parameter** Factor XI
Number of Participants 345
Number of Responders 266 **Response Rate** 77 %
Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	0	0	0	260	6

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	262	22	0.27	16.2	6 - 37	20	-0.43
two-stage clotting assay	3	19			19 - 19		
Hyphen-Biomed Cephen	1	19					
IL HemosIL SynthAsil	2	19			19 - 19		
one-stage clotting assay	259	22	0.27	16.2	6 - 37	20	-0.44
IL HemosIL APTT lyophilised silica	1	18					
IL HemosIL APTT-SP liquid silica	12	19	0.94	13.3	16 - 31		
IL HemosIL SynthAsil	84	22	0.37	12.4	16 - 36	20	-0.61
Sekisui Coagpia APTT-FS	1	27					
Siemens Actin	2	19			18 - 20		
Siemens Actin FS	33	22	0.54	11.5	18 - 28		
Siemens Actin FSL	20	22	0.84	13.5	16 - 31		
Siemens Pathromtin SL	32	27	1.39	23.4	12 - 37		
Stago Cephalin/Kaolin/CK Prest	38	20	0.54	13.2	15 - 25		
Stago Cephascreeen	5	24			17 - 30		
Stago PTT (automate)/STA APTT	23	19	0.75	15.0	6 - 24		
Tcoag Automated APTT	1	27					
Tcoag TriniClot APTT S	3	23			13 - 23		
Tcoag TriniClot APTT-HS	4	24			22 - 31		



Coagulation Factor - I


Factor XI

Sample No 18.114
Sample Details Plasma of a patient with a moderate haemophilia B
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 25-June-2020
Homogeneity 5.8 % **Homogeneity Parameter** Factor IX
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 345
Number of Responders 266 **Response Rate** 77 %
Comments Two participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 One participant did not report a result for this sample.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	74	42	52	89	8

Your Classification Borderline Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	263	58	0.44	9.8	31 - 162	58	-0.10
two-stage clotting assay	3	49			49 - 57		
Hyphen-Biomed Cephen	1	57					
IL HemosIL SynthAsil	2	49			49 - 49		
one-stage clotting assay	260	58	0.44	9.7	31 - 162	58	-0.12
IL HemosIL APTT lyophilised silica	1	59					
IL HemosIL APTT-SP liquid silica	13	54	1.47	7.8	46 - 107		
IL HemosIL SynthAsil	85	59	0.57	7.2	41 - 69	58	-0.31
Sekisui Coagpia APTT-FS	1	63					
Siemens Actin	2	52			49 - 54		
Siemens Actin FS	33	57	1.12	9.1	47 - 75		
Siemens Actin FSL	20	54	1.50	9.9	40 - 60		
Siemens Pathromtin SL	32	57	1.11	8.9	31 - 69		
Stago Cephalin/Kaolin/CK Prest	38	62	0.94	7.5	50 - 74		
Stago Cephascreen	5	66			52 - 85		
Stago PTT (automate)/STA APTT	22	64	2.21	13.0	54 - 162		
Tcoag Automated APTT	1	61					
Tcoag TriniClot APTT S	3	57			50 - 65		
Tcoag TriniClot APTT-HS	4	54			52 - 61		







Coagulation Factor - I

Factor XI

Z-score plot



Z-score history



Coagulation Factor - I


Factor XII

Sample No 18.113
Sample Details Plasma with a low Factor XI level
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-April-2021
Homogeneity 0.0 % **Homogeneity Parameter** Factor XI
Number of Participants 345
Number of Responders 243 **Response Rate** 70 %
Comments Two participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	237	1	1	1	3

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	240	96	0.73	9.4	56 - 134	100	0.51
two-stage clotting assay	3	87			87 - 97		
Hyphen-Biomed Cepen	1	97					
IL HemosIL SynthAsil	2	87			87 - 87		
one-stage clotting assay	237	96	0.74	9.5	56 - 134	100	0.50
IL HemosIL APTT lyophilised silica	1	100					
IL HemosIL APTT-SP liquid silica	12	99	5.58	15.7	77 - 127		
IL HemosIL SynthAsil	83	99	0.90	6.6	82 - 111	100	0.18
Sekisui Coagpia APTT-FS	1	86					
Siemens Actin	2	93			91 - 95		
Siemens Actin FS	31	94	1.94	9.2	82 - 117		
Siemens Actin FSL	15	98	3.36	10.7	86 - 134		
Siemens Pathromtin SL	30	91	1.81	8.7	65 - 110		
Stago Cephalin/Kaolin/CK Prest	35	92	2.08	10.7	56 - 120		
Stago Cephascreen	6	95			80 - 99		
Stago PTT (automate)/STA APTT	12	101	6.68	18.4	76 - 125		
Tcoag Automated APTT	1	91					
Tcoag TriniClot APTT S	3	97			87 - 108		
Tcoag TriniClot APTT-HS	5	99			91 - 114		



Coagulation Factor - I

Factor XII

Sample No 18.114
Sample Details Plasma of a patient with a moderate haemophilia B
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 25-June-2020
Homogeneity 5.8 %

Homogeneity Parameter Factor IX

For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 345

Number of Responders 243


Response Rate 70 %

Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 One participant did not report a result for this sample.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	110	39	22	68	3

Your Classification Normal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	239	59	0.51	10.7	41 - 87	61	0.33
two-stage clotting assay	3	53			53 - 68		
Hyphen-Biomed Cephén	1	68					
IL HemosIL SynthAsil	2	53			53 - 53		
one-stage clotting assay	236	59	0.51	10.7	41 - 87	61	0.33
IL HemosIL APTT lyophilised silica	1	59					
IL HemosIL APTT-SP liquid silica	12	62	3.36	15.1	42 - 79		
IL HemosIL SynthAsil	83	61	0.48	5.7	48 - 73	61	-0.16
Sekisui Coagpia APTT-FS	1	52					
Siemens Actin	2	56			56 - 57		
Siemens Actin FS	31	57	1.58	12.3	44 - 77		
Siemens Actin FSL	15	54	1.74	9.9	41 - 76		
Siemens Pathromtin SL	30	53	1.18	9.7	41 - 62		
Stago Cephalin/Kaolin/CK Prest	35	59	1.38	11.1	43 - 87		
Stago Cephascreen	6	58			53 - 60		
Stago PTT (automate)/STA APTT	11	65	4.61	18.8	51 - 83		
Tcoag Automated APTT	1	55					
Tcoag TriniClot APTT S	3	60			57 - 62		
Tcoag TriniClot APTT-HS	5	57			55 - 71		




Coagulation Factor - I

Factor XII

Z-score plot



Z-score history



Coagulation Factor - II	Factor II
--------------------------------	------------------

Sample No 18.115
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 1.8 % **Homogeneity Parameter** PT
 For any method used for the measurement of this parameter with a **CV ≤ 6.0%** the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.


Number of Participants 249
Number of Responders 207 **Response Rate** 83 %

Comments
 One participant (**labcode 990**) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	202	0	0	0	5

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	206	96	0.63	7.6	79 - 124	86	-1.36
Clotting Assay	206	96	0.63	7.6	79 - 124	86	-1.36
I.L. HemosIL PT-Fibrinogen - HS Plus	1	83					
I.L. HemosIL Readiplastin	16	92	2.26	7.9	80 - 117	86	-0.86
I.L. HemosIL Recombiplastin 2G	64	93	1.03	7.1	79 - 113		
Other	1	100					
Sekisui Coagpia PT-N	1	93					
Siemens Innovin	44	101	1.11	5.9	87 - 114		
Siemens Pathromtin SL	1	96					
Siemens Thromborel S	22	100	1.43	5.4	80 - 124		
Stago (STA) Neoplastin CI	1	94					
Stago (STA) Neoplastin CI Plus	44	94	1.18	6.6	82 - 116		
Stago Neoplastin R	9	96			90 - 109		
Tcoag TriniCLOT PT Excel	1	105					
Tcoag TriniCLOT PT HTF	1	88					



Coagulation Factor - II


Factor II

Sample No 18.116
Sample Details Plasma with a low Factor X
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 11-March-2020
Homogeneity 4.8 % **Homogeneity Parameter** Factor X
 For any method used for the measurement of this parameter with a CV ≤ 16.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 249
Number of Responders 207 **Response Rate** 83 %
Comments One participant (**labcode 990**) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	4	0	0	198	5

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	206	23	0.23	11.8	13 - 71	19	-1.42
Clotting Assay	206	23	0.23	11.8	13 - 71	19	-1.42
I.L. HemosIL PT-Fibrinogen - HS Plus	1	22					
I.L. HemosIL ReadiPlastin	16	21	0.45	7.0	18 - 25	19	-1.25
I.L. HemosIL Recombiplastin 2G	64	22	0.24	7.0	13 - 27		
Other	1	25					
Sekisui Coagpia PT-N	1	19					
Siemens Innovin	44	25	0.42	8.9	15 - 30		
Siemens Pathromtin SL	1	23					
Siemens Thromborel S	22	25	0.94	13.9	20 - 30		
Stago (STA) Neoplastin CI	1	23					
Stago (STA) Neoplastin CI Plus	44	22	0.38	9.1	19 - 71		
Stago Neoplastin R	9	21			18 - 25		
Tcoag TriniCLOT PT Excel	1	23					
Tcoag TriniCLOT PT HTF	1	19					




Coagulation Factor - II

Factor II

Z-score plot



Z-score history




Coagulation Factor - II **Factor V**

Sample No 18.115
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 1.8 % **Homogeneity Parameter** PT
 For any method used for the measurement of this parameter with a CV ≤ 6.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 249
Number of Responders 224 **Response Rate** 90 %
Comments One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	216	1	1	0	6

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	223	92	0.81	10.4	72 - 130	79	-1.35
Clotting Assay	223	92	0.81	10.4	72 - 130	79	-1.35
I.L. HemosIL PT-Fibrinogen - HS Plus	1	89					
I.L. HemosIL ReadiPlastin	16	86	2.13	7.9	74 - 96	79	-0.97
I.L. HemosIL Recombiplastin 2G	67	88	1.14	8.5	73 - 108		
Sekisui Coagpia PT-N	1	92					
Siemens Innovin	50	97	1.81	10.5	77 - 123		
Siemens Thromborel S	27	99	3.30	13.9	72 - 130		
Stago (STA) Neoplastin CI	1	109					
Stago (STA) Neoplastin CI Plus	48	93	1.26	7.5	76 - 112		
Stago Neoplastin R	10	92	2.48	6.8	85 - 111		
Tcoag Simplastin HTF	1	78					
Tcoag TriniCLOT PT Excel	1	108					



Coagulation Factor - II

Factor V

Sample No 18.116
Sample Details Plasma with a low Factor X
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 11-March-2020
Homogeneity 4.8 %

Homogeneity Parameter Factor X

For any method used for the measurement of this parameter with a CV ≤ 16.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 249


Number of Responders 224 **Response Rate** 90 %

Comments One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	168	23	13	14	6

Your Classification Borderline Normal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	223	75	0.62	9.9	26 - 98	62	-1.73
Clotting Assay	223	75	0.62	9.9	26 - 98	62	-1.73
I.L. HemosIL PT-Fibrinogen - HS Plus	1	72					
I.L. HemosIL Readiplastin	16	71	1.67	7.5	62 - 79	62	-1.72
I.L. HemosIL Recombiplastin 2G	67	72	0.92	8.3	59 - 90		
Sekisui Coagpia PT-N	1	68					
Siemens Innovin	50	79	1.39	9.9	58 - 96		
Siemens Thromborel S	27	72	2.23	12.8	26 - 89		
Stago (STA) Neoplastin CI	1	84					
Stago (STA) Neoplastin CI Plus	48	77	1.29	9.3	66 - 98		
Stago Neoplastin R	10	75	2.30	7.8	67 - 83		
Tcoag Simplastin HTF	1	73					
Tcoag TriniCLOT PT Excel	1	93					




Coagulation Factor - II

Factor V

Z-score plot



Z-score history



Coagulation Factor - II

Factor VII

Sample No 18.115
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 1.8 %

Homogeneity Parameter PT

For any method used for the measurement of this parameter with a CV ≤ 6.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 249


Number of Responders 218 **Response Rate** 88 %

Comments
One participant (labcode 990) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	214	0	0	0	4

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	217	108	0.68	7.5	87 - 136	101	-0.91
Clotting Assay	217	108	0.68	7.5	87 - 136	101	-0.91
I.L. HemosIL PT-Fibrinogen - HS	1	118					
I.L. HemosIL PT-Fibrinogen - HS Plus	1	101					
I.L. HemosIL ReadIPlastin	17	105	1.38	4.3	96 - 129	101	-0.94
I.L. HemosIL Recombiplastin 2G	65	105	1.10	6.7	90 - 119		
Other	1	115					
Sekisui Coagpia PT-N	1	115					
Siemens Innovin	49	110	1.35	6.9	87 - 125		
Siemens Thromborel S	27	108	2.40	9.2	88 - 132		
Stago (STA) Neoplastin CI	1	91					
Stago (STA) Neoplastin CI Plus	42	112	1.63	7.5	94 - 136		
Stago Neoplastin R	10	110	1.46	3.4	105 - 114		
Tcoag Simplastin HTF	1	105					
Tcoag TriniCLOT PT Excel	1	118					



Coagulation Factor - II


Factor VII

Sample No 18.116
Sample Details Plasma with a low Factor X
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 11-March-2020
Homogeneity 4.8 % **Homogeneity Parameter** Factor X
 For any method used for the measurement of this parameter with a CV ≤ 16.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 249
Number of Responders 218 **Response Rate** 88 %
Comments One participant (**labcode 990**) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	4	0	1	208	5

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	217	22	0.46	25.3	5 - 94	15	-1.23
Clotting Assay	217	22	0.46	25.3	5 - 94	15	-1.23
I.L. HemosIL PT-Fibrinogen - HS	1	18					
I.L. HemosIL PT-Fibrinogen - HS Plus	1	21					
I.L. HemosIL ReadiPlastin	17	17	0.38	7.6	15 - 25	15	-1.37
I.L. HemosIL Recombiplastin 2G	65	17	0.22	8.4	5 - 23		
Other	1	35					
Sekisui Coagpia PT-N	1	26					
Siemens Innovin	49	21	0.39	10.2	16 - 28		
Siemens Thromborel S	27	24	0.68	11.8	20 - 94		
Stago (STA) Neoplastin CI	1	22					
Stago (STA) Neoplastin CI Plus	42	29	0.40	7.1	23 - 34		
Stago Neoplastin R	10	22	0.46	5.4	20 - 27		
Tcoag Simplastin HTF	1	20					
Tcoag TriniCLOT PT Excel	1	31					







Coagulation Factor - II

Factor VII

Z-score plot



Z-score history



Coagulation Factor - II **Factor X**

Sample No 18.115
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 1.8 % **Homogeneity Parameter** PT
 For any method used for the measurement of this parameter with a CV ≤ 6.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.


Number of Participants 249
Number of Responders 216 **Response Rate** 87 %

Comments One participant (labcode 990) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 Two participants reported a result above the measurement range (> [value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	208	1	2	0	5

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	214	94	0.64	8.0	67 - 123	87	-0.88
Clotting Assay	214	94	0.64	8.0	67 - 123	87	-0.88
I.L. HemosIL PT-Fibrinogen	1	99					
I.L. HemosIL PT-Fibrinogen - HS Plus	1	93					
I.L. HemosIL ReadiPlastin	17	89	1.46	5.4	80 - 102	87	-0.34
I.L. HemosIL Recombiplastin 2G	64	90	1.20	8.5	75 - 123		
Other	1	112					
Sekisui Coagpia PT-N	1	97					
Siemens Innovin	45	98	1.22	6.7	67 - 121		
Siemens Pathromtin SL	1	102					
Siemens Thromborel S	26	97	1.41	6.0	85 - 122		
Stago (STA) Neoplastin CI	2	97			87 - 106		
Stago (STA) Neoplastin CI Plus	44	92	1.00	5.8	82 - 115		
Stago Neoplastin R	9	99			91 - 105		
Tcoag Simplastin HTF	1	88					
Tcoag TriniCLOT PT Excel	1	104					



Coagulation Factor - II

Factor X

Sample No 18.116
Sample Details Plasma with a low Factor X
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 11-March-2020
Homogeneity 4.8 %

Homogeneity Parameter Factor X

For any method used for the measurement of this parameter with a CV ≤ 16.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 249

Number of Responders 216


Response Rate 87 %

Comments One participant (labcode 990) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 Two participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	1	0	0	210	5

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	214	11	0.11	12.1	8 - 109	10	-0.73
Clotting Assay	214	11	0.11	12.1	8 - 109	10	-0.73
I.L. HemosIL PT-Fibrinogen	1	11					
I.L. HemosIL PT-Fibrinogen - HS Plus	1	8					
I.L. HemosIL ReadiPlastin	17	10	0.29	9.9	8 - 12	10	-0.12
I.L. HemosIL Recombiplastin 2G	64	10	0.17	10.5	8 - 109		
Other	1	11					
Sekisui Coagpia PT-N	1	11					
Siemens Innovin	44	10	0.31	15.8	8 - 17		
Siemens Pathromtin SL	1	11					
Siemens Thromborel S	26	11	0.34	12.3	9 - 18		
Stago (STA) Neoplastin CI	2	11			10 - 12		
Stago (STA) Neoplastin CI Plus	45	11	0.21	9.8	9 - 15		
Stago Neoplastin R	9	10			8 - 11		
Tcoag Simplastin HTF	1	9					
Tcoag TriniCLOT PT Excel	1	10					




Coagulation Factor - II

Factor X

Z-score plot



Z-score history





Von Willebrand Factor Parameters


VWF antigen

Sample No 18.117
Sample Details Plasma of a patient with a type 2 Von Willebrand Disease
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 27-June-2020
Homogeneity 0.0 % **Homogeneity Parameter** vWF antigen
Number of Participants 356
Number of Responders 300 **Response Rate** 84 %
Comments One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	3	2	23	268	4

Your Classification Borderline Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	299	35	0.41	16.5	15 - 59	42	1.22
Latex Immuno Assay	265	35	0.45	16.8	15 - 44	42	1.21
I.L. VWF	82	39	0.36	6.6	21 - 44	42	0.80
Siemens VWF	85	29	0.59	15.3	15 - 42		
Stago / Roche Liatest vWF	98	35	0.29	6.5	20 - 43		
Enzyme Immuno Assay	18	37	2.09	19.2	27 - 59		
BioMerieux Vidas vWF	2	42			41 - 42		
DG-EIA vWF	2	36			33 - 39		
Homemade (DAKO antibodies)	9	37			28 - 59		
Homemade (other)	1	33					
Reaads VWF antigen	1	32					
Stago Asserachrom vWF	2	46			45 - 47		
Technoclone vWF Ag	1	27					
CLIA	16	33	0.82	8.0	28 - 41		
I.L. AcuStar VWF	16	33	0.82	8.0	28 - 41		



Von Willebrand Factor Parameters

VWF antigen

Z-score history



Von Willebrand Factor Parameters


VWF Ristocetin Cofactor activity

Sample No 18.117
Sample Details Plasma of a patient with a type 2 Von Willebrand Disease
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 27-June-2020
Homogeneity 0.0 % **Homogeneity Parameter** vWF antigen
Number of Participants 356
Number of Responders 150 **Response Rate** 42 %
Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	0	0	1	149	0

Your Classification None


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	141	20	0.51	23.7	7 - 37		
ELISA	5	15			13 - 36		
ABP vWF:Rco assay	1	15					
Other	1	36					
Stago vWF:Ristocetin Cofactor activity	3	14			13 - 17		
Agglutination	58	18	0.86	28.9	7 - 34		
Biodata vWF assay	6	19			12 - 31		
Hart Biological VWF Assay	1	26					
Homemade	3	24			23 - 31		
Other	2	20			19 - 22		
Siemens vWF Reagent	46	17	0.85	27.0	7 - 34		
Turbidimetric	40	21	0.37	8.8	19 - 30		
Homemade	5	21			20 - 30		
I.L. HemosIL vWF Rco activity	35	21	0.38	8.4	19 - 28		
Aggregation	14	20	2.33	34.7	11 - 37		
Biogenics VWF: RiCoF	2	15			11 - 18		
Chronolog vWF assay	4	17			14 - 37		
Helena Laboratories vWF:RiCoF assay	7	21			15 - 31		
Other	1	18					
CLIA	24	24	0.51	8.4	18 - 29		
Homemade	2	24			22 - 26		
I.L. AcuStar VWF Rco	22	24	0.52	8.3	18 - 29		



Von Willebrand Factor Parameters

VWF Ristocetin Cofactor activity

Z-score history



Von Willebrand Factor Parameters

VWF activity


Sample No 18.117
Sample Details Plasma of a patient with a type 2 Von Willebrand Disease
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 27-June-2020
Homogeneity 0.0 % **Homogeneity Parameter** vWF antigen
Number of Participants 356
Number of Responders 161 **Response Rate** 45 %

Comments One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.
 One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	1	0	2	155	3

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	159	21	0.45	21.8	12 - 51	30	1.99
Elisa	10	25	3.17	32.1	17 - 37		
ABP vWF assay	8	26			17 - 37		
Homemade	1	19					
Reaads vWF activity	1	23					
Latex ImmunoAssay	57	26	1.07	24.6	17 - 51	30	0.57
Homemade	2	20			19 - 22		
I.L. Latex vWF activity	52	27	1.11	23.7	17 - 51	30	0.44
Other	3	18			18 - 19		
Particle ligand-receptor assay	92	18	0.21	8.8	12 - 26		
Siemens Innovance vWF Ac	91	18	0.21	8.8	12 - 26		
Unknown	1	17					



Von Willebrand Factor Parameters

VWF activity

Z-score history





Von Willebrand Factor Parameters


VWF Collagen Binding Assay

Sample No 18.117
Sample Details Plasma of a patient with a type 2 Von Willebrand Disease
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 27-June-2020
Homogeneity 0.0 % **Homogeneity Parameter** vWF antigen
Number of Participants 356
Number of Responders 79 **Response Rate** 22 %
Comments None

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	2	0	1	74	2

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	79	23	0.67	20.7	15 - 66	27	0.82
ELISA	57	24	0.86	21.4	15 - 66	27	0.54
Corgenix / Reaads CBA	1	21					
DG-EIA CBA	1	23					
Homemade (DAKO antibodies)	9	24			15 - 39		
Homemade (other)	2	26			20 - 31		
Hyphen Biomed CB activity	5	25			17 - 30		
Life Diagnostics vWF:CBA assay	5	22			16 - 66		
Stago Asserachrom vWF:CBA	9	21			15 - 24		
Tecnoclone vWF:CBA assay	25	26	1.05	16.3	18 - 62	27	0.27
CLIA	22	21	0.93	16.7	16 - 26		
I.L. Acustar CBA	22	21	0.93	16.7	16 - 26		



Von Willebrand Factor Parameters

VWF Collagen Binding Assay

Z-score history





Von Willebrand Factor Parameters


VWF Factor VIII


Sample No 18.117
 Sample Details Plasma of a patient with a type 2 Von Willebrand Disease
 Prior Use Prior Use: None
 Unit Units: % or IU/dL
 Expiry Date 27-June-2020
 Homogeneity 0.0 % Homogeneity Parameter vWF antigen
 Number of Participants 356
 Number of Responders 270 Response Rate 76 %
 Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	0	0	0	264	6

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	266	7	0.12	23.7	2 - 20	7	0.29
One-stage clotting assay	245	7	0.12	23.3	3 - 20	7	0.26
Two-stage clotting assay	2	7			7 - 7		
Chromogenic assay	19	6	0.60	36.2	2 - 13		



Von Willebrand Factor Parameters
VWF Factor VIII
Z-score history

vWF Multimers

Lack HMW	6
Undetectable	0
Lack MMW and HMW	1
Normal distribution	34
No selection	4

Comments

Despite this was a sample from a patient with a type 2 Von Willebrand Disease, most of the participants found a normal multimer distribution.

INTERPRETATION
Ratio vWF:RiCoF / vWF antigen

<< 1	52
< 1	115
~ 1	34
> 1	0

Ratio Factor VIII / vWF antigen

<< 1	156
< 1	41
~ 1	2
> 1	3

FINAL CONCLUSION
General Classification

No conclusion	49
normal	2
Type 1	40
Type 2	142
Type 3	0
Nothing indicated	83

Your Result	Type 2
-------------	--------

Type 2 sub-classification

Type 2A	7
Type 2B	13
Type 2M	3
Type 2N	61

Your Result	Type 2N
-------------	---------



Comments

In total 316 participants reported results in this survey (participation rate: 89%).

The plasma used in this survey was from a patient diagnosed with a Type 2 Von Willebrand Disease.

The majority of participants who gave a final conclusion classified this sample as a Type 2 VWD (61%). Seventeen percent classified this sample as a Type 1 VWD. Twenty-one percent was unable, based on their test(s), to classify this sample.

The type 2 VWD classification corresponds with the low VWF RCo activity / VWF antigen ratio.

About 26% (!) of the participants did not give a final conclusion.

Factor XIII

Factor XIII activity (qualitative)

Sample No 18.120
Sample Details Plasma with a Factor XIII level < 2%
Prior Use Prior Use: 2018-1
Unit Units:
Expiry Date 30-June-2019
Homogeneity 5.8 % **Homogeneity Parameter** Factor XIII
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 168
Number of Responders 22 **Response Rate** 13 %
Comments None

Overview of the combinations of activator and lysis agents used

Activator

Lysis Agent	Human Trombin	Bovine Trombin	Calcium Chloride	Agkistrodon rhodastoma venom	Other
Acetic Acid	0	2	2	0	0
Chloro Acetic Acid	0	0	3	0	0
Urea	2	0	13	0	0
Other	0	0	0	0	0

Results

Abnormal (FXIII < 1%)	20
Normal (FXIII > 1%)	2

Your Result	
-------------	--

Your Classification None

Factor XIII
Factor XIII activity (qualitative)

Sample No	18.121		
Sample Details	Normal Coagulation Control Plasma		
Prior Use	Prior Use: None		
Unit	Units:		
Expiry Date	30-November-2019		
Homogeneity	0.0 %	Homogeneity Parameter	APTT
Number of Participants	168		
Number of Responders	22	Response Rate	13 %
Comments	None		

Overview of the combinations of activator and lysis agents used

Lysis Agent	Activator				
	Human Trombin	Bovine Trombin	Calcium Chloride	Agkistrodon rhodastoma venom	Other
Acetic Acid	0	2	2	0	0
Chloro Acetic Acid	0	0	3	0	0
Urea	2	0	13	0	0
Other	0	0	0	0	0

Results

Abnormal (FXIII < 1%)	0
Normal (FXIII > 1%)	22

Your Result	
-------------	--

Your Classification None

Factor XIII	Factor XIII activity (quantitative)
--------------------	--

Sample No 18.120
Sample Details Plasma with a Factor XIII level < 2%
Prior Use Prior Use: 2018-1
Unit Units: % or IU/dL
Expiry Date 30-June-2019
Homogeneity 5.8 % **Homogeneity Parameter** Factor XIII
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.


Number of Participants 168
Number of Responders 97 **Response Rate** 58 %

Comments One participant (**labcode 216**) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation. Only 4 out of 26 participants reported a value < 2.5%. All other participants used a higher lower limit of detection.
 One participant did not report a result for this sample.
 For the most frequently used reagent (n >= 10) the results of sample 18.120 are good comparable with those of sample 18.46 in survey 2018-M1.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	0	0	0	96	0

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	70	9	1.16	84.9	0 - 36	6	-0.44
Homemade	1	0					
Siemens Factor XIII (- blank correction)	51	10	1.42	79.2	0 - 36	6	-0.56
Siemens Factor XIII (+ blank correction)	10	10	3.27	85.5	0 - 21		
Stago Factor XIII	4	4			3 - 4		
Technoclone Technochrom FXIII	4	5			0 - 7		



Factor XIII
Factor XIII activity (quantitative)


Sample No 18.121
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 0.0 % **Homogeneity Parameter** APTT
Number of Participants 168
Number of Responders 97 **Response Rate** 58 %

Comments One participant (**labcode 216**) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	89	4	0	4	0

Your Classification Normal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	96	83	1.16	10.9	8 - 118	92	0.93
Homemade	1	82					
Other	1	74					
Reanal-Ker Rea-chrom FXIII	1	73					
Siemens Factor XIII (- blank correction)	70	82	1.34	10.9	8 - 118	92	1.02
Siemens Factor XIII (+ blank correction)	12	83	1.79	6.0	76 - 90		
Stago Factor XIII	5	104			75 - 117		
Technoclone Technochrom FXIII	6	89			69 - 99		




Factor XIII

Factor XIII activity (quantitative)

Z-score plot



Z-score history



Factor XIII

Factor XIII antigen

Sample No 18.120
Sample Details Plasma with a Factor XIII level < 2%
Prior Use Prior Use: 2018-1
Unit Units: % or IU/dL
Expiry Date 30-June-2019
Homogeneity 5.8 % **Homogeneity Parameter** Factor XIII
 For any method used for the measurement of this parameter with a CV ≤ 19.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.


Number of Participants 168
Number of Responders 39 **Response Rate** 23 %

Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.
 For the most frequently used reagent (n >= 10) the results of sample 18.120 are good comparable with those of sample 18.46 in survey 2018-M1.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	0	0	0	39	0

Your Classification None

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	19	2	0.44	66.8	0 - 6		
Enzyme Immuno Assay	1	4					
Other	1	4					
Latex Immuno Assay	18	2	0.44	67.7	0 - 6		
I.L. HemosIL Factor XIII	10	2	0.42	58.9	1 - 4		
MBL Hexamate Factor XIII	3	4			1 - 6		
Stago / Kamiya K-Assay Factor XIII	5	3			0 - 4		



Factor XIII


Factor XIII antigen

Sample No 18.121
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 0.0 % **Homogeneity Parameter** APTT
Number of Participants 168
Number of Responders 39 **Response Rate** 23 %
Comments One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	36	0	0	3	0

Your Classification None


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	38	77	1.71	10.9	65 - 117		
Enzyme Immuno Assay	2	89			76 - 102		
Other	1	102					
Reanal-Ker Factor XIII Elisa	1	76					
Latex Immuno Assay	36	77	1.62	10.1	65 - 117		
I.L. HemosIL Factor XIII	28	74	0.94	5.4	65 - 115		
MBL Hexamate Factor XIII	3	84			71 - 87		
Stago / Kamiya K-Assay Factor XIII	5	107			106 - 117		




Factor XIII

Factor XIII antigen

Z-score plot



Z-score history



Fibrinolysis - I

Plasminogen activity

Sample No 18.122
Sample Details Plasma with a Plasmin Inhibitor level < 5%
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 31-March-2020
Homogeneity 1.3 %

Homogeneity Parameter Plasmin Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 4.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 147

Number of Responders 120


Response Rate 82 %

Comments One participant reported a result below the detection limit (<[value]). This result was excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	3	0	7	109	1

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	119	44	0.78	15.5	25 - 88	51	1.06
Hyphen Bioned Biophen Plasminogen	1	51					
I.L. HemosIL Plasminogen	42	49	0.75	8.0	25 - 59	51	0.54
Siemens Plasminogen	49	42	0.92	12.2	34 - 87		
Stago/Roche Plasminogen	27	38	0.79	8.7	32 - 88		



Fibrinolysis - I

Plasminogen activity

Sample No 18.123
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: 2018-M1
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 2.0 %

Homogeneity Parameter Antithrombin

For any method used for the measurement of this parameter with a CV ≤ 6.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 147

Number of Responders 120


Response Rate 82 %

Comments One participant reported a result above the measurement range (> [value]). This result was excluded in the statistical evaluation.
 For the most frequently used reagents (n >= 10) the results of sample 18.123 are good comparable with those of sample 18.48 in survey 2018-M1.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	114	1	1	3	1

Your Classification Normal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	119	89	0.56	5.5	33 - 120	91	0.48
Hyphen Bioned Biophen Plasminogen	1	97					
i.L. HemosIL Plasminogen	42	88	0.81	4.8	77 - 94	91	0.89
Siemens Plasminogen	49	91	0.91	5.6	39 - 120		
Stago/Roche Plasminogen	27	88	1.11	5.2	33 - 96		




Fibrinolysis - I

Plasminogen activity

Z-score plot



Z-score history





Fibrinolysis - I

Plasmin Inhibitor

Sample No 18.122
Sample Details Plasma with a Plasmin Inhibitor level < 5%
Prior Use Prior Use: None
Unit Units: % or IU/dL
Expiry Date 31-March-2020
Homogeneity 1.3 %

Homogeneity Parameter Plasmin Inhibitor

For any method used for the measurement of this parameter with a CV ≤ 4.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 147


Number of Responders 95 **Response Rate** 65 %

Comments Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	1	0	1	91	2

Your Classification Abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	70	9	0.87	61.9	0 - 105	9	-0.13
Hyphen Biomed Biophen Antiplasmin	2	14			12 - 15		
I.L. HemosIL Plasmin Inhibitor	24	10	1.22	48.1	2 - 23	9	-0.29
Other	1	16					
Siemens Antiplasmin	19	5	1.31	87.4	0 - 17		
Stago/Roche Antiplasmin	24	12	1.61	54.8	3 - 105		



Fibrinolysis - I

Plasmin Inhibitor

Sample No 18.123
Sample Details Normal Coagulation Control Plasma
Prior Use Prior Use: 2018-M1
Unit Units: % or IU/dL
Expiry Date 30-November-2019
Homogeneity 2.0 % **Homogeneity Parameter** Antithrombin
 For any method used for the measurement of this parameter with a CV ≤ 6.7% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.


Number of Participants 147
Number of Responders 95 **Response Rate** 65 %

Comments For the most frequently used reagents (n >= 10) the results of sample 18.123 are good comparable with those of sample 18.48 in survey 2018-M1.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	88	2	2	1	2

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	95	101	1.05	8.1	25 - 131	103	0.23
Hyphen Biomed Biophen Antiplasmin	2	106			101 - 111		
I.L. HemosIL Plasmin Inhibitor	28	102	1.36	5.7	75 - 131	103	0.17
Other	1	110					
Sekisui Coagpia Antiplasmin	1	94					
Siemens Antiplasmin	36	104	1.47	6.8	88 - 120		
Stago/Roche Antiplasmin	27	95	2.34	10.2	25 - 117		




■ Chromogenic




Fibrinolysis - I

Plasmin Inhibitor

Z-score plot



Z-score history



Fibrinolysis - II

PAI-1 antigen


Sample No 18.124
Sample Details Plasma with a low PAI-1 level
Prior Use Prior Use: None
Unit Units: ng/mL
Expiry Date 31-May-2020
Homogeneity 2.7 % **Homogeneity Parameter** PAI-1 antigen
 For any method used for the measurement of this parameter with a CV ≤ 9.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 66
Number of Responders 29 **Response Rate** 44 %
Comments Two participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	20	0	1	8	0

Your Classification

Borderline abnormal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	27	4.3	0.60	57.8	0.7 - 8.6	3.4	-0.34
Hyphen Biomed Elitest PAI-1 antigen	1	6.1					
Hyphen Biomed Zymutest PAI-1 antige	10	5.8	0.51	22.5	3.9 - 7.8		
Stago Asserachrom PAI-1	4	1.6			1.0 - 2.2		
Tcoag TriniLIZE PAI-1 antigen	4	4.5			3.5 - 8.6		
Technoclone Technozym PAI-1 antigen	8	2.8			0.7 - 8.5	3.4	



Fibrinolysis - II
PAI-1 antigen

Sample No 18.125
Sample Details Plasma with an elevated PAI-1 level
Prior Use Prior Use: None
Unit Units: ng/mL
Expiry Date 31-May-2020
Homogeneity 4.3 %

Homogeneity Parameter PAI-1 antigen

For any method used for the measurement of this parameter with a $CV \leq 14.3\%$ the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 66


Number of Responders 29 **Response Rate** 44 %

Comments Several participants reported a result above the measurement range (> [value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	8	0	1	19	1

Your Classification Abnormal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	22	60.6	9.27	57.3	4.7 - 119.6	88.6	0.80
Hyphen Biomed Elitest PAI-1 antigen	1	84.8					
Hyphen Biomed Zymutest PAI-1 antige	7	92.0			49.0 - 110.8		
Stago Asserachrom PAI-1	5	34.0			32.0 - 39.1		
Tcoag TriniLIZE PAI-1 antigen	4	35.4			31.3 - 38.0		
Technoclone Technozym PAI-1 antigen	5	84.0			4.7 - 119.6	88.6	




Fibrinolysis - II

PAI-1 antigen

Z-score plot



Z-score history



Fibrinolysis - II
PAI-1 activity

Sample No 18.124
Sample Details Plasma with a low PAI-1 level
Prior Use Prior Use: None
Unit Units: IU/mL or ng/mL
Expiry Date 31-May-2020
Homogeneity 2.7 % **Homogeneity Parameter** PAI-1 antigen
 For any method used for the measurement of this parameter with a CV \leq 9.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 66
Number of Responders 28 **Response Rate** 42 %

Comments One participant (labcode 9907150) most likely exchanged samples or results. These results were excluded in the statistical evaluation.
 Several participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	20	0	0	7	1

Your Classification None

Unit: IU/mL	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	19	4.9	1.77	126.2	0.0 - 22.1		
Chromogenic	13	6.7	3.02	130.8	0.0 - 22.1		
Sekisui Spectrolyse PAI-1	1	5.6					
Siemens Berichrom PAI-1	6	0.3			0.0 - 0.8		
Stago Stachrom PAI-1	6	14.1			1.3 - 22.1		
BIA/ELISA	6	2.7			2.4 - 3.4		
Technoclone Technozym PAI-1 activity	6	2.7			2.4 - 3.4		

No data for graph

Unit: ng/mL	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	2	0.8			0.1 - 1.5		
BIA/ELISA	2	0.8			0.1 - 1.5		
Hyphen Biomed Zymutest PAI-1 activit	2	0.8			0.1 - 1.5		

Fibrinolysis - II

PAI-1 activity

Sample No 18.125
Sample Details Plasma with an elevated PAI-1 level
Prior Use Prior Use: None
Unit Units: IU/mL or ng/mL
Expiry Date 31-May-2020
Homogeneity 4.3 % **Homogeneity Parameter** PAI-1 antigen
 For any method used for the measurement of this parameter with a CV ≤ 14.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 66
Number of Responders 28 **Response Rate** 42 %
Comments One participant (labcode 9907150) most likely exchanged samples or results. These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	6	0	1	20	1

Your Classification None

Unit: IU/mL	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	25	26.1	4.22	64.8	4.1 - 45.9		
Chromogenic	14	17.1	5.16	90.1	4.1 - 35.8		
Sekisui Spectrolyse PAI-1	1	22.3					
Siemens Berichrom PAI-1	7	4.6			4.1 - 4.8		
Stago Stachrom PAI-1	6	32.5			22.6 - 35.8		
BIA/ELISA	11	37.4	2.61	18.5	31.8 - 45.9		
Tcoag TriniLIZE PAI-1 activity	4	32.0			31.8 - 33.2		
Technoclone Technozym PAI-1 activity	7	43.7			32.5 - 45.9		

No data for graph


Unit: ng/mL	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	3	45.0			23.2 - 196.0		
BIA/ELISA	3	45.0			23.2 - 196.0		
Hyphen Biomed Zymutest PAI-1 activit	3	45.0			23.2 - 196.0		




Fibrinolysis - II

PAI-1 activity

Z-score plot



Z-score history



Fibrinolysis - II


t-PA antigen

Sample No 18.124
Sample Details Plasma with a low PAI-1 level
Prior Use Prior Use: None
Unit Units: ng/mL
Expiry Date 31-May-2020
Homogeneity 2.7 % **Homogeneity Parameter** PAI-1 antigen
 For any method used for the measurement of this parameter with a CV ≤ 9.0% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.
Number of Participants 66
Number of Responders 23 **Response Rate** 35 %
Comments None

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	19	0	2	2	0

Your Classification Normal

	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	23	7.4	0.70	36.5	3.7 - 18.1	7.0	-0.13
Homemade	1	6.1					
Hyphen Biomed Zymutest t-PA antigen	5	8.8			5.0 - 11.0		
Stago Asserachrom t-PA	9	9.4			7.5 - 18.1		
Technoclone Technozym t-PA antigen	8	4.8			3.7 - 7.0	7.0	





Fibrinolysis - II

t-PA antigen

Sample No 18.125
Sample Details Plasma with an elevated PAI-1 level
Prior Use Prior Use: None
Unit Units: ng/mL
Expiry Date 31-May-2020
Homogeneity 4.3 %

Homogeneity Parameter PAI-1 antigen

For any method used for the measurement of this parameter with a CV ≤ 14.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual.

Number of Participants 66

Number of Responders 23


Response Rate 35 %

Comments Two participants reported a result below the detection limit (<[value]). These results were excluded in the statistical evaluation.

Classification Overview	Normal	BorderLine normal	Borderline abnormal	Abnormal	No classification
Total	19	1	1	1	1

Your Classification Normal


	n	assigned value	Uncert.	CV (%)	range	your result	z-score
Total Group	21	4.1	0.62	55.2	1.7 - 11.1	2.8	-0.61
Homemade	1	2.5					
Hyphen Biomed Zymutest t-PA antigen	5	3.8			3.0 - 7.3		
Stago Asserachrom t-PA	8	6.7			3.0 - 11.1		
Technoclone Technozym t-PA antigen	7	2.0			1.7 - 3.0	2.8	



Fibrinolysis - II

t-PA antigen

Z-score plot



Z-score history

